|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Creabilis Therapeutics Appoints Dr. Eliot Forster as its New Chief Executive Officer
9/29/2010 6:32:52 AM
LUXEMBOURG, September 29, 2010 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, today announced the appointment of Eliot Forster as its new Chief Executive Officer. Dr Forster brings to Creabilis significant drug development experience having brought a number of molecules to market.
Dr Forster has close to 20 years industry experience in biotechnology and pharmaceutical companies. He was most recently the CEO of Solace Pharmaceuticals, a US-based biotech. Prior joining Solace, Dr Forster was Head of EU Development and of Development Operations in the EU & Asia at Pfizer. During his career at Pfizer Dr Forster was integral to bringing a number of drugs to market, including Celebrex(R) (celecoxib), Bextra(R) (valcecoxib) and Relpax(R) (eletriptan).
Dr Forster holds a PhD from Liverpool University and an M.B.A. from Henley Management College. He has held a number of Non-Executive Director roles in the biotech sector and is an advisor to the UKTI Life Sciences Strategy Board.
Commenting on his new role, Dr Eliot Forster said: "Creabilis has the potential to make a significant difference to the way serious skin diseases are treated. Our lead product, CT327, is advancing through the clinic and highlights the potential of our Low Systemic Exposure (LSE) technology to deliver innovative new chemical entities, targeting significant unmet medical needs. I very much look forward to working with the exceptional team at Creabilis and delivering on the undoubted promise of the Company's pipeline and underlying science."
George F. Horner III, Chairman of Creabilis, said: "We are delighted that Eliot has joined Creabilis. His proven drug development experience will be extremely valuable as we work to further advance of our exciting pipeline of clinical drug candidates. Eliot's appointment is another important step in Creabilis bringing highly innovative treatments for skin diseases to market."
About Creabilis SA
Creabilis is a clinical stage European biotechnology company creating highly innovative new drugs to tackle unmet medical needs in serious dermatological diseases. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of skin diseases.
Creabilis' lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company's LSE (Low Systemic Exposure) technology. LSE technology creates new chemical entities with ideal characteristics for topical application (high local concentrations combined with low systemic exposure). CT327 is currently in Phase II clinical trials in psoriasis and atopic dermatitis. The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions such as rheumatoid arthritis as well as severe psoriasis. Earlier stage projects include a number of highly promising candidates for dermatological and wider indications.
Creabilis is backed by some of Europe's most highly respected life sciences investors including Sofinnova Partners and Neomed.
|
|
|
|
|
|
|
|
|
|
|